Khaini (Smokeless Tobacco) Cessation - Management for a 33-Year-Old Male

What is Khaini and Why It Matters

Step 1 - Clinical Assessment Before Starting Cessation

Step 2 - The 5 A's Framework (Outpatient Delivery)

1. Ask - Confirm current khaini use pattern (frequency, amount per day, duration, any previous quit attempts)
2. Advise - Give clear, strong, personalized advice to quit. Emphasize oral cancer risk, cardiovascular risk, and reversibility of early mucosal lesions on cessation
3. Assess - Assess readiness and motivational stage (this patient is ready)
4. Assist - Provide behavioral counseling AND pharmacotherapy (combined approach is most effective)
5. Arrange - Schedule follow-up (at 1 week, 1 month, 3 months after quit date)

Step 3 - Behavioral Interventions (First-Line, Essential)

• Cessation counseling vs. minimal support: RR 1.76 (95% CI 1.44-2.16) - moderate certainty
• Brief advice vs. no support: RR 1.24 (95% CI 1.03-1.48) - moderate certainty

Recommended behavioral approaches:

• Explore ambivalence, strengthen motivation, build self-efficacy
• Even a 5-10 minute structured MI session significantly increases quit rates

• Identify triggers (stress, post-meal, work breaks - common khaini cues)
• Coping strategies for cravings: delay (urge typically peaks at 3-5 mins), distraction, deep breathing, substitute oral behaviors (sugar-free gum, sunflower seeds, toothpick)
• Restructure thoughts that minimize the habit

• India's iQuit/mTobaccoCessation platforms
• Particularly effective in the South Asian context per the India-based network meta-analysis (Krishnamoorthy et al., PMID 37195879)

• Structured 4-8 weekly sessions of 20-45 minutes
• Peer support, accountability, shared coping strategies

Step 4 - Pharmacotherapy (Evidence-Based, Adjunct to Counseling)

First-Line Options:

• Mechanism: Partial agonist at α4β2 nicotinic acetylcholine receptor - relieves withdrawal AND blocks nicotine reward
• Dose: 0.5 mg/day × 3 days → 0.5 mg BD × 4 days → 1 mg BD from Day 8 onwards
• Duration: 3-6 months (reduce relapse)
• Start 1-4 weeks before quit date
• Side effects: nausea (take with food + full glass of water), insomnia, vivid dreams
• Evidence in SLT: RR 1.35 (95% CI 1.08-1.68) vs. placebo (2025 Cochrane)
• For a 70 kg male with no cardiovascular disease, this is the optimal choice. - Fuster & Hurst's The Heart, 15th Ed.; Katzung's Pharmacology, 16th Ed.

• Evidence in SLT: RR 1.18 (95% CI 1.05-1.33) vs. placebo (low certainty)
• Preferred forms for khaini users (oral/buccal delivery mimics existing behavior):
  • Nicotine polacrilex gum (2 mg or 4 mg) - most practical for khaini users; mimics the oral fixation
  • Nicotine lozenge (2 mg)
  • Nicotine patch (transdermal) as background coverage + gum/lozenge for breakthrough cravings (combination NRT)
• The 2024 pilot RCT (Siddiqui et al., Addiction 2024) across Bangladesh, India, and Pakistan found behavioral support + NRT achieves ~12% biochemically verified abstinence at 26 weeks in SLT users including khaini users
• NRT gum is widely used in India (84% of NRT prescriptions in tobacco cessation clinics per the NMJI cohort study)

• 150 mg/day × 3 days → 150 mg BD
• Duration: 3-6 months; start 1-2 weeks before quit date
• Benefits: may blunt post-cessation weight gain
• Contraindicated if: seizure disorder, binge drinking, eating disorders
• Evidence in SLT cessation was not statistically significant in Cochrane 2025 (RR 0.89) - use if varenicline is not tolerated

Combination Therapy:

Step 5 - Withdrawal Management

Step 6 - Oral Health Referral (Critical for Khaini Users)

• Dental/oral medicine referral for full oral cavity examination
• Screen for: oral submucous fibrosis (OSF), leukoplakia, erythroplakia
• Biopsies of suspicious lesions as appropriate
• OSF management if present (pentoxifylline, intralesional steroids, physiotherapy for trismus)
• Regular 6-monthly oral surveillance

Step 7 - Relapse Prevention and Rehabilitation

• Set a firm quit date (within 1-2 weeks of initiating pharmacotherapy)
• Remove all khaini from the environment (social cues are powerful triggers)
• Identify high-risk situations: stress, peer pressure, alcohol use, post-meal
• Develop written coping plan for each trigger
• Family/social support: involve family members; ask them not to use tobacco around him
• Continue pharmacotherapy for minimum 3 months (preferably 6 months) to protect the maintenance phase
• Relapse counseling: frame relapse as a learning experience, not failure; restart treatment promptly
• Long-term follow-up: 6 months, 12 months post-quit-date

Summary Algorithm

Patient wants to quit khaini
        ↓
Assess: FTND + Oral exam + Motivational stage + Psychiatric screen
        ↓
5 A's framework at every visit
        ↓
BEHAVIORAL: Counseling (individual/group) + MI + Trigger management
        +
PHARMACOTHERAPY: Varenicline (preferred) OR NRT gum ± patch
        ↓
Set quit date → Start medications
        ↓
Follow-up: Week 1 → Month 1 → Month 3 → Month 6
        ↓
Oral medicine referral (leukoplakia/OSF screening)
        ↓
Relapse prevention plan + ongoing support

Key Evidence Summary